胰腺神经内分泌肿瘤治疗进展

Progress in Treatment of Pancreatic Neuroendocrine Tumors

摘要: 在我国，胰腺是神经内分泌肿瘤最为常见的发生部位。胰腺神经内分泌肿瘤(pancreatic neuroendocrine tumors，简称pNETs)是一类起源于胰腺多能神经内分泌干细胞的肿瘤，在所有胰腺肿瘤中所占的比例大约为1%~2%。随着公众健康意识的日益增长以及检测技术的不断进步，pNETs的发病率和检出率都在逐年升高，但针对pNETs的治疗目前仍以手术治疗为主要手段，并且根治性手术切除被公认为唯一可能彻底治愈pNETs的方法；但令人痛惜的是，很多患者在确诊时已进展至中晚期，已错过了行根治性手术的机会；幸运的是，目前结合其他化疗、放疗、免疫等非手术治疗，疗效也大幅提升。但提高对该病的认识，进行科学的“排兵布阵”，实行精准的个体化治疗，才更有利于提高该疾病的生存期。为了更精准地制定个体化治疗方案，本文就近年来胰腺神经内分泌肿瘤的治疗进展做一概述。

Abstract: In China, the pancreas is the most common site of neuroendocrine tumors. Pancreatic neuroendocrine tumors (PNETs) are a class of tumors originating from pancreatic pluripotent neuroendocrine stem cells, accounting for about 1% to 2% of all pancreatic tumors. With the growing awareness of public health and the continuous progress of detection technology, the incidence and detection rates of PNETs are increasing year by year. However, surgical treatment is still the main treatment for PNETs, and radical surgical resection is recognized as the only method that can completely cure PNETs; However, it is regrettable that many patients have progressed to the middle and late stage at the time of diagnosis, and have missed the opportunity of radical surgery. Fortunately, the curative effect has also been greatly improved in combination with other non-surgical treatments such as chemotherapy, radiotherapy and immunization. However, to improve the understanding of the disease, carry out scientific “troop arrangement”, and implement accurate and individualized treatment are more conducive to improving the survival time of the disease. In order to more accurately formulate individualized treatment, this article reviews the treatment progress of pancreatic neuroendocrine tumors in recent years.